Blood Loss, Postoperative, Blood Loss, Surgical
Conditions
Keywords
blood loss, Cesarean Section, Oxytocin, Tranexamic acid(Kapron), Etamsylate(Dicynon).
Brief summary
Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate, Pre-operative Administration.
Detailed description
Caesarean Delivery commonly referred to as caesarean section and occasionally caesarean birth is defined as the delivery of a foetus(es) through surgical incisions made through the anterior abdominal wall (technically referred to as laparotomy) and the anterior uterine wall (technically denoted to as hysterotomy). Obstetric Hemorrhage (Intra operative OR post operative bleeding)is still the major cause of maternal morbidity and mortality worldwide contributing to nearly 25% of direct maternal deaths. And accounts for 50% of maternal mortality in low-income countries. So many Strategies reducing the intraoperative blood loss or post operative blood loss could be helpful in decreasing the risks of blood transfusion and the postoperative maternal morbidity. So these Medications are such as Oxytocin, Carbetocin, Misoprostol, Prostaglandin F2 alpha, methylergonovine, Tranexamic acid and Etamsylate . have been tried before to control bleeding during and after Cesarean Section.
Interventions
DRUGOxytocin ,Tranexamic acid and Ethamsylate
Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
Sponsors
Egymedicalpedia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Pregnant females admitted for elective Cesarean Section. 2. Gestational age (38 to 41 weeks). 3. Age of the participants: 20 to 40 years. 4. Body Mass Index (18.5 - 29.9). 5. Singleton living fetus. 6. No medical disorders. 7. Informed written consent from the candidates.
Exclusion criteria
1. \- Medical and surgical disorders as thyroid dysfunction, which was excluded by routine thyroid function test (free T3, free T4, and thyroid-stimulating hormone(TSH), all of them should be within normal limits). 2. -Bleeding tendency, was excluded by platelet count, coagulation time, bleeding time, prothrombin time, partial thromboplastin time, and thrombin time (all should be within normal). 3. -Acute and chronic liver or kidney diseases; blood disorders, such as anemia. 4. -Allergy to Tranexamic acid or any drug used. 5. -Risk factors for PPH, such as polyhydramnios, fetal macrosomia, antepartum hemorrhage. 6. \- Abnormal placentae such as placenta previa and placental abruption. 7. -Pregnancy complications such as severe pre-eclampsia, Gestational HTN, Gestational DM, and multi Fetal pregnancies, those requiring blood transfusion. 8. \- Patients who refused spinal anesthesia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intraoperative and Post operative bleeding(defined as blood loss ≥500 cc) | First 2 hours after C-Section | Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level pre and post operatively. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sever PPH as bleeding is >1000 cc | first 24 hours after C-Section | Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level post operatively. |
Countries
Egypt
Outcome results
None listed